The University of Texas MD Anderson Cancer Center announced its new collaboration with GlaxoSmithKline to advance development of cancer immunotherapies.
The collaboration will focus on the identification of new therapeutic approaches, evaluation of patient outcomes in clinical testing, and utilization of resulting information to develop drugs that recruit the body’s own immune system against cancer.
{iframe}http://www.bioresearchonline.com/doc/gsk-partners-with-md-anderson-for-cancer-immunotherapies-development-0001{/iframe}